Aliases & Classifications for Substance Abuse

About this section

Substance Abuse, Aliases & Descriptions:

Name: Substance Abuse 9 11 3
 
Substance Abuse Problem 60


External Ids:

Disease Ontology9 DOID:302
NCIt38 C16522
SNOMED-CT55 66214007, 26416006
MeSH33 D019966
ICD9CM27 305

Summaries for Substance Abuse

About this section


Disease Ontology:9 A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning.

MalaCards based summary: Substance Abuse, also known as substance abuse problem, is related to anxiety disorder and antisocial personality disorder. An important gene associated with Substance Abuse is SLC6A2 (solute carrier family 6 (neurotransmitter transporter), member 2), and among its related pathways are Histidine metabolism and Tyrosine metabolism p.1 dopamine . The compounds pirlindole and pyrazoline have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and liver, and related mouse phenotypes are nervous system and behavior/neurological.

Wikipedia:63 Substance abuse, also known as drug abuse, is a patterned use of a drug in which the user consumes the... more...

Related Diseases for Substance Abuse

About this section

Diseases related to Substance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 76)
idRelated DiseaseScoreTop Affiliating Genes
1anxiety disorder31.2MAOA
2antisocial personality disorder31.2MAOA, HTR1B
3conduct disorder31.1MAOA, DRD5
4personality disorder30.9HTR1B, MAOA, MAOB
5generalized anxiety disorder30.7MAOA, SLC6A2
6bipolar disorder30.5MAOA, MAOB, DRD5, SLC6A2
7borderline personality disorder30.4MAOA, HTR1B
8panic disorder30.4SLC6A2, MAOA
9anorexia nervosa30.3SLC6A2, MAOA
10mood disorder30.2HTR1B, MAOA, MAOB, SLC6A2
11obesity30.1SLC6A2, MAOB, MAOA
12bulimia nervosa30.1MAOA, HTR1B
13alcohol dependence29.9MAOA, HTR1B, ADH4
14attention deficit-hyperactivity disorder29.9HTR1B, MAOA, DRD5, SLC6A2
15schizophrenia29.8HTR1B, MAOA, MAOB, DRD5, TDO2, SLC6A2
16hepatitis10.5
17alcohol abuse10.5
18oppositional defiant disorder10.4SLC6A2
19drug addiction10.4
20hepatitis c10.4
21cocaine abuse10.3
22pathological gambling10.3
23dementia10.3
24agoraphobia10.2SLC6A2, MAOA
25opioid dependence10.2
26cannabis abuse10.2
27opioid abuse10.2
28fetal alcohol syndrome10.2
29eating disorder10.2
30substance dependence10.2
31developmental disabilities10.2
32pure autonomic failure10.2MAOB, MAOA
33hepatic encephalopathy10.2MAOB, MAOA
34psychotic disorder10.1MAOA, MAOB
35asthma10.1
36hepatitis c virus10.1
37huntington disease10.1
38hiv-110.1
39brain injury10.1
40hepatitis b10.1
41liver disease10.1
42traumatic brain injury10.1
43avoidant personality disorder10.1
44multiple personality disorder10.1
45phencyclidine abuse10.1
46amphetamine abuse10.1
47antidepressant type abuse10.1
48polyhydramnios10.1
49barbiturate abuse10.1
50post-traumatic stress disorder10.1

Graphical network of the top 20 diseases related to Substance Abuse:



Diseases related to substance abuse

Symptoms for Substance Abuse

About this section

Drugs & Therapeutics for Substance Abuse

About this section

Drug clinical trials:

Search ClinicalTrials for Substance Abuse

Search NIH Clinical Center for Substance Abuse

Genetic Tests for Substance Abuse

About this section

Anatomical Context for Substance Abuse

About this section

MalaCards organs/tissues related to Substance Abuse:

31
Testes, Brain, Liver, Heart, Kidney, Hypothalamus, Pituitary, Subthalamic nucleus

Animal Models for Substance Abuse or affiliated genes

About this section

MGI Mouse Phenotypes related to Substance Abuse:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00036318.1MAOB, DRD5, TDO2, SLC6A2, MAOA
2MP:00053867.5SLC6A2, TDO2, MAOB, MAOA, HTR1B

Publications for Substance Abuse

About this section

Articles related to Substance Abuse:

(show top 50)    (show all 599)
idTitleAuthorsYear
1
Does a history of substance abuse and illness chronicity predict increased impulsivity in bipolar disorder? (25863910)
2015
2
Accuracy of popular media reporting on tobacco cessation therapy in substance abuse and mental health populations. (25814498)
2015
3
Treating substance abuse is not enough: Comorbidities in consecutively admitted female prisoners. (25770695)
2015
4
Service utilization of asians and other racial-ethnic groups: comparisons in a state substance abuse treatment system. (24093520)
2014
5
Substance Abuse, Violence, and HIV/AIDS (SAVA) Syndemic Effects on Viral Suppression Among HIV Positive Women of Color. (25397666)
2014
6
Criminal justice outcomes after engagement in outpatient substance abuse treatment. (24238717)
2014
7
The tangled branches (las ramas enredadas): sexual risk, substance abuse, and intimate partner violence among Hispanic men who have sex with men. (24084703)
2014
8
Referral for substance abuse treatment and depression improvement among patients with co-occurring disorders seeking behavioral health services in primary care. (24095002)
2014
9
The Relationship of State Medicaid Coverage to Medicaid Acceptance Among Substance Abuse Providers in the United States. (24407938)
2014
10
Cost-effectiveness of rapid HCV testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. (25291977)
2014
11
A review of existing treatments for substance abuse among the elderly and recommendations for future directions. (23471422)
2013
12
How the states stack up: disparities in substance abuse outpatient treatment completion rates for minorities. (23664124)
2013
13
Approaches to substance abuse in Cuba: Ricardo A. GonzA!lez MD PhD DrSc. Psychiatrist and consulting professor, Eduardo B. Ordaz. Psychiatric Hospital, Havana. Interviewed by Christina Mills. (24253343)
2013
14
Utilization of communication technology by patients enrolled in substance abuse treatment. (23107600)
2013
15
Substance abuse journal: new beginnings. (24159902)
2013
16
Future research needs for evaluating the integration of mental health and substance abuse treatment with primary care. (24042241)
2013
17
Substance use among women receiving post-rape medical care, associated post-assault concerns and current substance abuse: results from a national telephone household probability sample. (23380490)
2013
18
Work needed to close gaps in coverage for mental health, substance abuse treatment. (24386795)
2013
19
Does Substance Abuse Fall Exclusively Along the Externalizing Spectrum? (24328838)
2013
20
The provider perception inventory: psychometrics of a scale designed to measure provider stigma about HIV, substance abuse, and MSM behavior. (23082899)
2013
21
Gene-environment correlation in the development of adolescent substance abuse: selection effects of child personality and mediation via contextual risk factors. (23398757)
2013
22
Employment status of veterans receiving substance abuse treatment from the U.S. Department of Veterans Affairs. (23370624)
2013
23
Predictors of retention in a drug-free unit/substance abuse treatment in prison. (23706657)
2013
24
Substance screening and referral for substance abuse treatment in an integrated mental health care program. (23280462)
2013
25
Comment on: pilot evaluation of a substance abuse prevention group intervention for at-risk bariatric surgery candidates. (23477955)
2013
26
Substance abuse as a risk factor for violence in mental illness: some implications for forensic psychiatric practice and clinical ethics. (23722099)
2013
27
Substance Abuse Treatment, HIV/AIDS, and the Continuum of Response for People Who Inject Drugs. (23243517)
2012
28
Depression as a mediator of the association between substance abuse and negative parenting of fathers. (22243417)
2012
29
Affective Awareness in Parenting of Fathers with Co-Occurring Substance Abuse and Intimate Partner Violence. (23710257)
2012
30
Organizational consequences of staff turnover in outpatient substance abuse treatment programs. (22154028)
2012
31
Changing pattern of substance abuse in patients attending a de-addiction centre in north India (1978-2008). (22825602)
2012
32
Substance abuse among migrant workers of Thai-Laos border, Thailand. (23140041)
2012
33
Community capacity assessment in preventing substance abuse: a participatory approach. (23193506)
2012
34
How to measure outcome in clinical trials of substance abuse treatment. (22372699)
2012
35
Culturally competent substance abuse treatment with transgender persons. (22873185)
2012
36
Substance abuse and movement disorders: complex interactions and comorbidities. (23030352)
2012
37
The dangers of substance abuse in adolescents with chronic kidney disease: a review of the literature. (22558679)
2012
38
A snapshot of North Carolina's public mental health, developmental disabilities, and substance abuse service system. (22779165)
2012
39
Disparities in completion of substance abuse treatment among Latino subgroups in Los Angeles County, CA. (22658303)
2012
40
Chronic illness histories of adults entering treatment for co-occurring substance abuse and other mental health disorders. (22211340)
2012
41
Resources and training in outpatient substance abuse treatment facilities. (22154031)
2012
42
Relationship of substance abuse to dependence in the U.S. general population. (22456242)
2012
43
Models of neurological disease (substance abuse): self-administration in monkeys. (22382996)
2011
44
Increasing ethnic minority participation in substance abuse clinical trials: lessons learned in the National Institute on Drug Abuse's Clinical Trials Network. (21988575)
2011
45
Editors' introduction: Identifying and assessing promising practices for criminal justice clients--California Substance Abuse Research Consortium (SARC) meetings, 2010. (22185034)
2011
46
Gender differences and conduct disorder among American Indian adolescents in substance abuse treatment. (12733762)
2003
47
Diagnosing antisocial personality disorder among substance abusers: the scid versus the MCMI-II. (11727884)
2001
48
A functionally deficient DRD2 variant [Ser311Cys] is not linked to alcoholism and substance abuse. (9650635)
1998
49
Substance abuse vulnerability and D2 receptor genes. (7681236)
1993
50
The antecedents of women's crack cocaine abuse: family substance abuse, sexual abuse, depression and illicit drug use. (8246316)
1993

Variations for Substance Abuse

About this section

Expression for genes affiliated with Substance Abuse

About this section
Search GEO for disease gene expression data for Substance Abuse.

Pathways for genes affiliated with Substance Abuse

About this section

Pathways related to Substance Abuse according to GeneCards Suite gene sharing:

(show all 19)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
histamine biosynthesis36
9.6MAOB, MAOA
29.6MAOB, MAOA
3
Show member pathways
choline degradation I36
glycine biosynthesis III36
serine and glycine biosynthesis36
glycine betaine degradation36
glycine biosynthesis36
9.6MAOA, MAOB
4
Show member pathways
citrulline-nitric oxide cycle36
arginine degradation I (arginase pathway)36
proline degradation36
glutamine degradation I36
proline biosynthesis I36
superpathway of citrulline metabolism36
proline biosynthesis II (from arginine)36
citrulline biosynthesis36
arginine degradation VI (arginase 2 pathway)36
Urea cycle and metabolism of amino groups36
asparagine biosynthesis I36
4-hydroxyproline degradation I36
citrulline degradation36
9.6MAOB, MAOA
5
Show member pathways
9.6MAOA, MAOB
69.6MAOA, MAOB
79.6MAOB, MAOA
89.6MAOA, MAOB
99.2MAOA, HTR1B
10
Show member pathways
9.1DRD5, HTR1B
11
Show member pathways
phenylalanine utilization36
noradrenaline and adrenaline degradation36
phenylalanine degradation IV36
9.1ADH4, MAOA, MAOB
12
Show member pathways
9.1MAOB, MAOA, ADH4
13
Show member pathways
9.1MAOB, MAOA, ADH4
14
Show member pathways
9.1ADH4, MAOA, MAOB
15
Show member pathways
Serotonin Transporter Activity36
9.1SLC6A2, TDO2, MAOA
16
Show member pathways
tryptophan degradation X (mammalian, via tryptamine)36
2-amino-3-carboxymuconate semialdehyde degradation to glutaryl-CoA36
tryptophan degradation36
glutaryl-CoA degradation36
serotonin degradation36
NAD de novo biosynthesis36
superpathway of melatonin degradation36
tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde36
tryptophan utilization I36
melatonin degradation I36
9.0TDO2, MAOB, MAOA
17
Show member pathways
9.0TDO2, MAOB, MAOA
18
Show member pathways
8.5TDO2, MAOB, MAOA, ADH4
19
Show member pathways
8.3HTR1B, MAOA, MAOB, DRD5

Compounds for genes affiliated with Substance Abuse

About this section

Compounds related to Substance Abuse according to GeneCards Suite gene sharing:

(show top 50)    (show all 151)
idCompoundScoreTop Affiliating Genes
1pirlindole4310.0MAOA, MAOB
2pyrazoline4310.0MAOB, MAOA
3toloxatone4310.0MAOB, MAOA
4(r)-(-)-deprenyl hydrochloride599.9MAOA, MAOB
5iproniazid43 1210.9MAOA, MAOB
6phenethylamine,439.9MAOA, MAOB
7bifemelane hydrochloride599.9MAOB, MAOA
8lazabemide hydrochloride599.9MAOB, MAOA
9rasagiline mesylate599.9MAOB, MAOA
10brofaromine439.9MAOA, MAOB
11isocarboxazid43 1210.9MAOA, MAOB
124,6-Dihydroxyquinoline249.9MAOB, MAOA
131-methyl-4-phenyl-2,3-dihydropyridinium439.9MAOA, MAOB
141,4-diphenyl-2-butene439.8MAOA, MAOB
15lazabemide439.8MAOA, MAOB
16m-tyramine439.7MAOB, MAOA, SLC6A2
17p-chloroamphetamine439.7MAOA, SLC6A2, MAOB
18nomifensine43 28 1211.7SLC6A2, MAOB, MAOA
19phentermine43 1210.7MAOA, SLC6A2, MAOB
20d amphetamine439.7MAOA, MAOB, SLC6A2
21mdma439.7SLC6A2, MAOB, MAOA
22mhpg439.7SLC6A2, MAOB, MAOA
23homovanillic acid43 2410.6MAOA, SLC6A2, MAOB
241 methyl 4 phenylpyridinium439.6MAOA, SLC6A2, MAOB
25sertraline43 28 49 24 1213.6SLC6A2, MAOB, MAOA
265-hydroxyindoleacetic acid43 2410.6MAOB, SLC6A2, MAOA
27tyramine43 28 2411.6MAOA, MAOB, SLC6A2
28oxazolidinone439.6MAOA, MAOB
29amitriptyline43 28 49 1212.6MAOB, MAOA, SLC6A2
30methamphetamine43 49 1211.4MAOB, SLC6A2, MAOA
316-hydroxydopamine439.4MAOA, MAOB, SLC6A2
32amphetamine43 49 1211.3SLC6A2, MAOA, MAOB
335-Hydroxykynurenamine249.3MAOB, MAOA
34mptp439.3SLC6A2, MAOB, MAOA
35clomipramine43 49 1211.2HTR1B, MAOA, SLC6A2
36paroxetine43 49 28 1212.2MAOA, HTR1B, SLC6A2
37citalopram43 49 24 1212.2SLC6A2, MAOB, MAOA
38tryptamine43 28 2411.2MAOB, HTR1B, MAOA
39Serotonin249.2MAOB, MAOA, HTR1B
40methylphenidate43 49 1211.2MAOB, DRD5, SLC6A2, MAOA
41catecholamine439.1MAOA, DRD5, SLC6A2, MAOB
42ropinirole43 1210.1DRD5, HTR1B, MAOB
43apomorphine28 43 1211.0MAOB, DRD5, HTR1B
44maoa438.9MAOB, SLC6A2, MAOA, HTR1B
45fluoxetine43 49 28 1211.9SLC6A2, MAOB, MAOA, HTR1B
46amine438.8MAOA, MAOB, HTR1B, SLC6A2
47levodopa43 129.7MAOB, DRD5, MAOA, HTR1B
48norepinephrine43 24 1210.6SLC6A2, DRD5, MAOB, MAOA
49dopamine43 28 24 1211.3MAOB, SLC6A2, MAOA, DRD5, HTR1B
505-hydroxytryptamine438.2HTR1B, SLC6A2, TDO2, MAOB, MAOA

GO Terms for genes affiliated with Substance Abuse

About this section

Biological processes related to Substance Abuse according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1negative regulation of serotonin secretionGO:00140639.3MAOB, HTR1B
2response to ethanolGO:00454719.2MAOB, HTR1B
3xenobiotic metabolic processGO:00068059.1ADH4, MAOA, MAOB
4response to cocaineGO:00422209.0DRD5, HTR1B
5synaptic transmissionGO:00072688.4SLC6A2, DRD5, MAOA, HTR1B
6small molecule metabolic processGO:00442818.2TDO2, MAOB, MAOA, ADH4

Molecular functions related to Substance Abuse according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1primary amine oxidase activityGO:00081319.6MAOB, MAOA

Products for genes affiliated with Substance Abuse

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies
  • Proteins
  • Kits and Assays

Sources for Substance Abuse

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCIt
39NDF-RT
42NINDS
43Novoseek
45OMIM
46OMIM via Orphanet
50PubMed
51QIAGEN
56SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet